Markers of preeclampsia and the relationship to cardiovascular disease: review of the twenty-first century literature

References

• Sibai BM. Hypertension in pregnancy. Clin Obstet Gynecol 1999;42:421.
   Google Scholar
• Cheng MH, Wang PH. Placentation abnormalities in the pathophysiology of preeclampsia. Exp Rev Mol Diagn 2009;9:37–49.
   PubMed Web of Science ®Google Scholar
• Preeclampsia Foundation. 2009. http://www.preeclampsia.org/statistics.asp.
   Google Scholar
• Groopman J. The preeclampsia puzzle. The New Yorker. www.jeromegroopman.com/tpt.html. Last accessed 21 September 2009.
   Google Scholar
• Duley L. The global impact of pre-eclampsia and eclampsia. Semin Perinatol 2009;33:130–137.
   PubMed Web of Science ®Google Scholar
• Karumanchi SA, Lindheimer MD. Advances in the understanding of eclampsia. Curr Hypertens Rep 2008;10:305–312.
   PubMedGoogle Scholar
• Sibai BM, Caritis SN, Hauth J; for the NICHD Maternal-Fetal Medicine Units Network. What we have learned about preeclampsia. Semin Perinatol 2003;27:239–246.
   PubMed Web of Science ®Google Scholar
• ACOG Committee on Practice Bulletins – Obstetrics. ACOG practice bulletin. Diagnosis and management of preeclampsia and eclampsia. Obstet Gynecol 2002;99:159–167.
   PubMed Web of Science ®Google Scholar
• Gabbe SG. Obstetrics: normal and problem pregnancies. 5th ed.Philadelphia, PA: Churchill Livingstone; 2007. p 866.
   Google Scholar
• Wagner LK. Diagnosis and management of preeclampsia. Am Fam Phys 2004;70:2317–2324.
   PubMed Web of Science ®Google Scholar
• Sibai BM, Ramadan MK, Usta I, Salama M, Mercer BM, Friedman SA. Maternal morbidity and mortality in 442 pregnancies with hemolysis, elevated liver enzymes, and low platelets (HELLP syndrome). Am J Obstet Gynecol 1993;169:1000–1006.
   PubMed Web of Science ®Google Scholar
• Jacquemyn Y, Jochems L, Duiker E, Bosmans JL, Van Hoof V, Van Capenhout C. Long-term renal function after HELLP syndrome. Gynecol Obstet Invest 2004;57:117.
   PubMed Web of Science ®Google Scholar
• Padden MO. ‘HELLP syndrome: recognition and perinatal management’. Am Fam Phys 1999;60:829–836, 839.
   PubMed Web of Science ®Google Scholar
• Valensise H, Vasapollo B, Gagliardi G, Novelli GP. Early and late preeclampsia: two different maternal hemodynamic states in the latent phase of the disease. Hypertension 2008;52:873.
   PubMed Web of Science ®Google Scholar
• Brown DH. Pre-eclampsia: a mistake of trophoblastic cells for tumour cells? Med Hypotheses 1999;53:124–126.
   PubMedGoogle Scholar
• Hladunewich M, Karumanchi SA, Lafayette R. Pathophysiology of the clinical manifestations of preeclampsia. Clin J Am Soc Nephrol 2007;2:543–549.
   PubMed Web of Science ®Google Scholar
• Davidson JM, Homuth, V, Jeyabalan A, Conrad P, Karumanchi SA, Quaggin S, Dechend R, Luft FC. New aspects in the pathophysiology of preeclampsia. J Am Soc Nephrol 2004;15:2440–2448.
   PubMedGoogle Scholar
• Sibai BM, Mercer B, Sarinoglu C. Severe preeclampsia in the second trimester: recurrence risk and long-term prognosis. Am J Obstet Gynecol 1991;165:1408.
   PubMed Web of Science ®Google Scholar
• Hannaford P, Ferry S, Hirsch S. CVD sequelae of toxaemia of pregnancy. Heart 1997;77:154–158.
   PubMed Web of Science ®Google Scholar
• Suzuki H, Watanabe Y, Arima H, Kobayashi K, Ohno Y, Kanno Y. Short- and long-term prognosis of blood pressure and kidney disease in women with a past history of preeclampsia. Clin Exp Nephrol 2008;12:102–109.
   PubMed Web of Science ®Google Scholar
• Conde-Agudelo A, Villar J, Lindheimer M; World Health Organization. Systematic review of screening tests for preeclampsia. Obstet Gynecol 2004;104:1367–1391.
   PubMed Web of Science ®Google Scholar
• Lindheimer MD, Umans JG. Explaining and predicting preeclampsia. N Engl J Med 2006;355:1056–1058.
   PubMed Web of Science ®Google Scholar
• Torry DS, Wang HS, Wang TH, Caudle MR, Torry RJ. Preeclampsia is associated with reduced serum levels of placenta growth factor. Am J Obstet Gynecol 1998;179:1539–1544.
   PubMed Web of Science ®Google Scholar
• Torry DS, Leavenworth J, Chang M, Maheshwari V, Groesch K, Ball ER, Torry RJ. Angiogenesis in implantation. J Assist Reprod Genet 2007;24:303–315.
   PubMed Web of Science ®Google Scholar
• Redman CW, Sargent IL. Latest advances in understanding preeclampsia. 2005;308:1592–1594.
   Google Scholar
• Ouyang YQ, Li SJ, Zhang Q, Cai HB, Chen HP. Interactions between inflammatory and oxidative stress in preeclampsia. Science 2005;308:1592–1594.
   PubMedGoogle Scholar
• Chambers JC, Fusi L, Malik IS, Haskard DO, De Swiet M, Kooner JS. Association of maternal endothelial dysfunction with preeclampsia. JAMA 2001;285:1607–1612.
   PubMed Web of Science ®Google Scholar
• Treloar SA, Cooper DW, Brennecke SP, Grehan MM, Martin NG. An Australian twin study of the genetic basis of preeclampsia and eclampsia. Am J Obstet Gynecol 2001;184:374–381.
   PubMedGoogle Scholar
• Hiltunen LM, Laivuori H, Rautanen A, Kaaja R, Kere J, Krusius T, Paunio M, Rasi V. Blood group AB and factor V Leiden as risk factors for pre-eclampsia: a population based nested case-control study. Thromb Res 2009;124:167–173.
   PubMed Web of Science ®Google Scholar
• Li H, Gu B, Zhang Y, Lewis DF, Wang Y. Hypoxia-induced increase in soluble Flt-1 production correlates with enhanced oxidative stress in trophoblast cells from the human placenta. Placenta 2005;26:210–217.
   PubMed Web of Science ®Google Scholar
• Herse F, Staff AC, Hering L, Müller DN, Luft FC, Dechend R. AT1-receptor autoantibodies and uteroplacental RAS in pregnancy and pre-eclampsia. J Mol Med 2008;86:697–703.
   PubMed Web of Science ®Google Scholar
• Maynard SE, Qian C, Lim KH, England LJ, Yu KF, Schisterman EF, Thadhani R, Sachs BP, Epstein FH, Sibai BM, Sukhatme VP, Karumanchi SA. Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med 2004;350:672–683.
   PubMedGoogle Scholar
• Ramsay JE, Stewart F, Greer IA, Sattar N. Microvascular dysfunction: a link between preeclampsia and maternal coronary heart disease. BJOG 2003;110:1029–1031.
   PubMed Web of Science ®Google Scholar
• Wolf M, Hubel CA, Lam C, Sampson M, Ecker JL, Ness RB, Rajakumar A, Daftary A, Shakir ASM, Seely EW, Roberts JM, Sukhatme VP, Karumanchi SA, Thadhani R. Preeclampsia and future cardiovascular disease: potential role of altered angiogenesis and insulin resistance. J Clin Endocrinol Metab 2004;89:6239–6243.
   PubMed Web of Science ®Google Scholar
• Wilson BJ, Watson MS, Prescott GJ, Sunderland S, Campbell DM, Hannaford P, Smith WCS. Hypertensive diseases of pregnancy and risk of hypertension and stroke in later life: results from cohort study. BMJ 2003;326:845–849.
   PubMed Web of Science ®Google Scholar
• McDonald SD, Malinowski A, Zhou O, Ysuf S, Devereaux PJ. Cardiovascular sequelae of preeclampsia/eclampsia: a systematic review and meta-analyses. Am Heart J 2008;156:918–930.
   PubMed Web of Science ®Google Scholar
• Garovic VD, Hayman SR. Hypertension in pregnancy: an emerging risk factor for CVD disease. Nephrology 2007;3:613–622.
   Google Scholar
• Rodie VA, Freeman DJ, Sattar N, Greer IA. Pre-eclampsia and cardiovascular disease: metabolic syndrome of pregnancy? Atherosclerosis 2004;175:189–202.
   PubMed Web of Science ®Google Scholar
• Haukkamaa L, Minna Salminen M, Laivuori H, Leinonen H, Hiilesmaa V, Kaaja R. Risk for subsequent coronary artery disease after preeclampsia. Am J Cardiol 2004;93:805–808.
   PubMed Web of Science ®Google Scholar
• Kestenbaum B, Seliger SL, Easterling TR, Gillen DL, Critchlow CW, Stehman-Breen CO, Schwartz SM. Cardiovascular and thromboembolic events following hypertensive pregnancy. Am J Kid Dis 2003;42:982–989.
   PubMed Web of Science ®Google Scholar
• Bellamy L, Casas JP, Hingorani AD, Williams DJ. Pre-eclampsia and risk of CVD disease and cancer in later life: systematic review and meta-analysis. BMJ 2007;335:974–985.
   PubMed Web of Science ®Google Scholar
• Wolf M, Kettyle E, Sandler L, Ecker JL, Roberts J, Thadhani R. Obesity and preeclampsia: the potential role of inflammation. Obstet Gynecol 2001;98:757–762.
   PubMed Web of Science ®Google Scholar
• Smith GCS, Pell JP, Walsh D. Pregnancy complications and maternal risk of ischaemic heart disease: a retrospective cohort study of 129,290 births. Lancet 2001;357:2002–2006.
   PubMed Web of Science ®Google Scholar
• Kanno S, Oda N, Abe M, Tera Y, Ito M, Shitara K, Tabayashi K, Shibuya M, Sato Y. Roles of two VEGF receptors, Flt-1 and KDR, in the signal transduction of VEGF effects in human vascular endothelial cells. Oncogene 2000;19:2138–2146.
   PubMed Web of Science ®Google Scholar
• Lim JH, Kim SY, Park SY, Yang JH, Kim M, Ryu HM. Effective prediction of preeclampsia by a combined ratio of angiogenesis-related factors. Obstet Gynecol 2008;111:1403–1409.
   PubMed Web of Science ®Google Scholar
• Zygmunt M, Herr F, Munstedt K, Lang U, Liang OD. Angiogenesis and vasculogenesis in pregnancy. Reprod Biol 2003;110:S10–S18.
   Google Scholar
• Mutter WP, Karumanchi SA. Molecular mechanisms of preeclampsia. Microvasc Res 2008;75:1–8.
   PubMed Web of Science ®Google Scholar
• Cross JC, Werb Z, Fisher SJ. Implantation and the placenta: key pieces of the development puzzle. Science 1994;266:1508–1518.
   PubMed Web of Science ®Google Scholar
• Maynard SE, Min JY, Merchan J, Lim KH, Li J, Mondal S, Libermann TA, Morgan JP, Sellke FW, Stillman IE, Epstein FH, Sukhatme VP, Karumanchi SA. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest 2003;111:649–658.
   PubMed Web of Science ®Google Scholar
• Baumann MU, Bersinger NA, Mohaupt MG, Raio L, Gerber S, Surbeck DV. First-trimester serum levels of soluble endoglin and soluble fms-like tyrosine kinase-1 as first-trimester markers for late-onset preeclampsia. Am J Obstet Gynecol 2008;199:266.e1–266.e6.
   PubMed Web of Science ®Google Scholar
• Dimitrakova E, Milchev N, Batashki I, Karumanchi SA. Cause-effect relationships between circulating placental angiogenic proteins and serum IL-2, IL-6 and IL-10 levels in pregnant women with preeclampsia. Akush Ginekol (Sofiia) 2007;46:4–8.
   PubMedGoogle Scholar
• Kim YN, Lee DS, Jeong DH, Sung MS, Kim KT. The relationship of the level of circulating antiangiogenic factors to the clinical manifestations of preeclampsia. Prenat Diagn in press.
   Google Scholar
• Levine RJ, Thadhani R, Qian C, Lam C, Lim KH, Yu KF, Blink AL, Sachs BP, Epstein FH, Sibai BM, Sukhatme VP, Karumanchi A. Urinary placental growth factor and risk of preeclampsia. JAMA 2005;293:77–85.
   PubMed Web of Science ®Google Scholar
• Lim JH, Kim SY, Park SY, Lee MH, Yang JH, Kim MY, Chung JH, Lee SW, Ryu HM. Soluble endoglin and transforming growth factor-β1 in women who subsequently developed preeclampsia. Prenat Diagn in press.
   Google Scholar
• Muy-Rivera M, Vadachkoria S, Woelk GB, Qiu C, Mahomed K, Williams MA. Maternal plasma VEGF, sVEGF-R1, and PLGF concentrations in preeclamptic and normotensive pregnant Zimbabwean women. Physiol Res 2005;54:611–622.
   PubMed Web of Science ®Google Scholar
• Robinson CJ, Johnson DD. Soluble endoglin as a second-trimester marker for preeclampsia. Am J Obstet Gynecol 2007;197:174.e1–174.e5.
   PubMed Web of Science ®Google Scholar
• Qazi U, Lam C, Karumanchi SA, Petri M. Soluble Fms-like tyrosine kinase associated with preeclampsia in pregnancy in systemic.
   Google Scholar
• Shibata E, Rajakumar A, Powers RW, Larkin RW, Gilmour C, Bodnar LM, Crombleholme WR, Ness RB, Roberts JM, Hubel CA. Lupus erythematosus. J Rheumatol 2008;35:631–663.
   PubMedGoogle Scholar
• Shibata E, Rajakumar A, Powers RW, Larkin RW, Gilmour C, Bodnar LM, Crombleholme WR, Ness RB, Roberts JM, Hubel CA. Soluble fms-like tyrosine kinase 1 is increased in preeclampsia but not in normotensive pregnancies with small-for-gestational-age neonates: relationship to circulating placental growth factor. J Clin Endocrinol Metab 2005;90:4895–4903.
   PubMed Web of Science ®Google Scholar
• Teixeira PG, Cabral ACV, Andrade SP, Reis ZSN, Barroso da Cruz LP, Pereira JB, de Barcelos Martins BO, de Lima Rezende CA. Placental growth factor (PLGF) is a surrogate marker in preeclamptic hypertension. Hypertens Pregn 2008;27:65–73.
   PubMed Web of Science ®Google Scholar
• Nadar SK, Karalis I, Yemeni EA, Blann AD, Lip GYH. Plasma markers of angiogenesis in pregnancy induced hypertension. Thromb Haemost 2005;94:1071–1076.
   PubMed Web of Science ®Google Scholar
• Bills VL, Varet J, Millar A, Harper SJ, Soothill PW, Bates DO. Failure to up-regulate VEGF165b in maternal plasma is a first trimester predictive marker for pre-eclampsia. Clin Sci 2009;116:265–272.
   PubMed Web of Science ®Google Scholar
• Espinoza J, Romero R, Nien JK, Gomez R, Kusanovic JP, Gonçalves LF, Medina L, Edwin S, Hassan S, Carstens M, Gonzalez R. Identification of patients at risk for early onset and/or severe preeclampsia with the use of uterine artery Doppler velocimetry and placental growth factor. Am J Obstet Gynecol 2007;196:326.e1–326.e13.
   PubMed Web of Science ®Google Scholar
• Parra M, Rodrigo R, Barjj P, Bosco C, Fernandez V, Munoz H, Soto-Chacon E. Screening test for preeclampsia through assessment of uteroplacental blood flow and biochemical markers of oxidative stress and endothelial dysfunction. Am J Obstet Gynecol 2005;193:1486–1491.
   PubMed Web of Science ®Google Scholar
• Rana S, Karumanchi SA, Levine RJ, Venkatesha S, Rauh-Hain JA, Tamez H, Thadhan R. Sequential changes in antiangiogenic factors in early pregnancy and risk of developing preeclampsia. Hypertension 2007;50:137–142.
   PubMed Web of Science ®Google Scholar
• Stepan H, Ebert T, Schrey S, Reisenbüchler C, Stein S, Lossner U, Bluher M, Stumvoll M, Kratzsch J, Faber R, Fasshaue M. Serum levels of angiopoietin-related growth factor are increased in preeclampsia. Am J Hypertens 2009;22:314–318.
   PubMedGoogle Scholar
• Ong CYT, Liao AW, Cacho AM, Spencer K, Path FRC, Nicolaides KH. First-trimester maternal serum levels of placenta growth factor as predictor of preeclampsia and fetal growth restriction. Obstet Gynecol 2001;98:608–611.
   PubMed Web of Science ®Google Scholar
• Romero R, Nien JK, Espinoza J, Todem D, Fu W, Chung H, Kusanovic JP, Gotsch F, Erez O, Mazaki-tovi S, Gomez R, Edwin S, Haiworapongsa T, Levine RJ, Karumanchi A. A longitudinal study of angiogenic (placental growth factor) and anti-angiogenic (soluble endoglin and soluble VEGF receptor-1) factors in normal pregnancy and patients destined to develop preeclampsia and deliver a small-for-gestational-age neonate. J Matern Fetal Neonatal Med 2008;21:9–23.
   PubMed Web of Science ®Google Scholar
• Pandey A, Mann M. Proteomics to study genes and genomes. Nature 2000;405:837–846.
   PubMed Web of Science ®Google Scholar
• Blumenstein M, McMaster MT, Black MA, Wu S, Prakash R, Cooney J, McCowan LME, Cooper GJS, North RA. A proteomic approach identifies early pregnancy biomarkers for preeclampsia: novel linkages between a predisposition to preeclampsia and cardiovascular disease. Proteomics 2009;9:2929–2945.
   PubMed Web of Science ®Google Scholar
• Buhimschi IA, Zhao G, Funai EF, et al Proteomic profiling of urine identifies specific fragments of SERPINA1 and albumin as biomarkers of preeclampsia. Am J Obstet Gynecol 2008;199:551.e1–551.e16.
   PubMed Web of Science ®Google Scholar
• Sibai B, Romero R, Klebanoff MA, et al Maternal plasma concentrations of the soluble tumor necrosis factor receptor 2 are increased prior to the diagnosis of preeclampsia. Am J Obstet Gynecol 2009;200:630.e1–630.e8.
   PubMed Web of Science ®Google Scholar
• Romero R, Kusanovic JP, Than NG, et al First-trimester maternal serum PP13 in the risk assessment for preeclampsia. Am J Obstet Gynecol 2008;199:122.e1–122.e11.
   Web of Science ®Google Scholar
• Spencer K, Cowans NJ, Chefetz I, Tal J, Meiri H. First-trimester maternal serum PP-13, PAPP-A and second-trimester uterine artery Doppler pulsatility index as markers of pre-eclampsia. Ultrasound Obstet Gynecol 2007;29:128–134.
   PubMed Web of Science ®Google Scholar
• Zwahlen M, Gerber S, Bersinger NA. First trimester markers for pre-eclampsia: placental vs. non-placental protein serum levels. Gynecol Obstet Invest 2007;63:15–21.
   PubMed Web of Science ®Google Scholar
• Ng EKO, Tse Leung N, Tsui NBY, Lau TK, Panesar NS, Chiu RWL, Lo YMD. The concentration of circulating corticotropin-releasing hormone mrna in maternal plasma is increased in preeclampsia. Clin Chem 2003;49: 5:727–731.
   PubMed Web of Science ®Google Scholar
• Farina A, Sekizawa A, De Sanctis P, Purwosunu Y, Okai T, Cha DH, Kang JG, Vicenzi C, Tempesta A, Wibowo N, Valvassori L, Rizzo N. Gene expression in chorionic villous samples at 11 weeks'gestation from women destined to develop preeclampsia. Prenat Diagn 2008;28:956–961.
   PubMed Web of Science ®Google Scholar
• Purwosunu Y, Sekizawa A, Okazaki S, et al Prediction of preeclampsia by analysis of cell-free messenger RNA in maternal plasma. Am J Obstet Gynecol 2009;200:386.e1–386.e7.
   PubMed Web of Science ®Google Scholar
• Von Versen-Hoeynck FM, Hubel CA, Gallaher1 MJ, Gammill HS, Powers RW. Plasma levels of inflammatory markers neopterin, sialic acid, and C-reactive protein in pregnancy and preeclampsia. Am J Hypertens 2009;22:687–692.
   PubMed Web of Science ®Google Scholar
• Tjoa L, van Vugt JMG, Gob ATJJ, Blankenstein MA, Oudejans CBM, Wijk IJ. Elevated C-reactive protein levels during first trimester of pregnancy are indicative of preeclampsia and intrauterine growth restriction. J Reprod Immunol 2003;59:29–37.
   PubMed Web of Science ®Google Scholar
• Aris A, Benali S, Ouellet A, Moutquin JM, Leblanc S. Potential biomarkers of preeclampsia: inverse correlation between hydrogen peroxide and nitric oxide early in maternal circulation and at term in placenta of women with preeclampsia. Placenta 2009;30:342–347.
   PubMed Web of Science ®Google Scholar
• Chappell LC, Seed PT, Briley A, Kelly FJ, Hunt BJ, Charnock-Jones DS, Mallet AI, Poston L. A longitudinal study of biochemical variables in women at risk of preeclampsia. Am J Obstet Gynecol 2002;187:127–136.
   PubMed Web of Science ®Google Scholar
• Kenny LC, Dunn WB, Ellis DI, Myers J, Baker PN, Kell DB; the GOPEC Consortium. Novel biomarkers for pre-eclampsia detected using metabolomics and machine learning. Metabolomics 2005;1:227–234.
   Web of Science ®Google Scholar
• Noris M, Todeschini M, Cassis P, Pasta F, Cappellini A, Bonazzola S, Macconi D, Maucci R, Porrati F, Benigni A, Picciolo C, Remuzzi G. l-arginine depletion in preeclampsia orients nitric oxide synthase toward oxidant species. Hypertension 2004;43:614–622.
   PubMed Web of Science ®Google Scholar
• Shaarawy M, Didy HE. Thrombomodulin, plasminogen activator inhibitor type 1 (PAM) and fibronectin as biomarkers of endothelial damage in preeclampsia and eclampsia. Int J Gynecol Obstet 1996;55:135–139.
   PubMedGoogle Scholar
• Stamiliio DM, Sebdev HM, Morgan MA, Propert K, Macones GA. Can antenatal clinical and biochemical markers predict development of severe preeclampsia. Am J Obstet Gynecol 2000;182:589–594.
   PubMedGoogle Scholar
• Craici I, Wagner S, Garovic VD. Preeclampsia and future cardiovascular risk: formal risk factor or failed stress test? Ther Adv Cardiovasc Dis 2008;2:249–259.
   PubMedGoogle Scholar
• Teppa RJ, Ness RB, Crombleholme WR, Roberts JM. Free leptin is increased in normal pregnancy and further increased in preeclampsia. Metabolism 2000;49:1043–1048.
   PubMed Web of Science ®Google Scholar
• Levine RJ, Maynard SE, Qian C, Lim KH, England LJ, Yu KF, Schisterman EF, Thadhani R, Sachs BP, Epstein FH, Sibai BM, Sukhatme VK, Karumanchi SA. Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med 2004;350:672–683.
   PubMed Web of Science ®Google Scholar
• Roberts GM, Gammill H. PE and CVD disease in later life. Circulating angiogenic factors and the risk of preeclampsia. The Lancet 2005;366:961–962.
   PubMedGoogle Scholar